CCR2 and neoplasm: Consistent with these findings, we confirmed that PHGDH deficiency markedly reduced CCR2 levels in TEMs treated with AE17-TCM or A549-TCM (Fig. 7B and Supplementary Fig. S7B) as well as in TAMs isolated from Phgdhfl/flCx3cr1-Cre tumor-bearing mice (Fig. 7C).